Under 10% of people that would benefit from obesity jabs including Wegovy are able to get them, states the World Health Organization as it publishes its first advice on the medications.
Considering over a billion individuals worldwide currently obese, it is calling for increased and just access to GLP-1 medication.
According to projections, in excess of 2,000,000,000 will be living with obesity by 2030 unless action is taken.
"Our latest guidelines affirms that obesity is a chronic disease that can be addressed with thorough and ongoing treatment," stated its chief Tedros Adhanom Ghebreyesus.
Substantial prices, constrained manufacturing, and logistical bottlenecks are major obstacles to broad access to the jabs that can assist patients in reducing considerable weight, says the agency.
Weight-Loss Drug Shortage
Even under the present most optimistic scenario, the manufacturing of these medications would only suffice for approximately 100 million people – less than 10% of those who need them, per the health organization.
The recommendation urges nations and manufacturers to increase access, via measures including patent sharing.
Exclusive production rights on semaglutide – the core ingredient of the drug Wegovy – is scheduled to end in a number of nations in 2026.
How Obesity Jabs Operate
GLP-1 drugs mimick a biological compound to slow digestion, suppress the appetite and boost satiety so individuals consume fewer calories.
Individuals usually begin shedding pounds after several weeks of beginning the once-weekly jabs.
Studies points to people may put most of the weight back on within a year of discontinuing the medication, when their typical hunger come back.
Being above a healthy weight elevates your likelihood for contracting medical conditions, like type 2 diabetes, cardiovascular issues, stroke, and certain cancers.
Excess weight impacts people in all nations and was responsible for over three and a half million fatalities worldwide in 2024, per the health agency.
